{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:45:10Z","timestamp":1792471510863,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Extramammary Paget disease (EMPD) is a rare cutaneous intraepithelial adenocarcinoma, which is mostly distributed in areas with sweat gland cells and mainly occurs in the anogenital skin of women. The male genital tract involvement is extremely rare and often occurs with other malignant tumors. Paget\u2019s disease in the scrotum with sweat gland carcinoma is even rarer. In the first report of scrotal endocrine sweat gland carcinoma associated with Paget disease by Saidi et\u00a0al. in 1997, no more than 50 cases have been reported in the relevant research worldwide. Early EMPD combined with sweat gland carcinoma is mainly surgical treatment, and there is no standard treatment plan for advanced EMPD with sweat gland carcinoma. Previous article has reported that chemotherapy such as paclitaxel, fluorouracil, platinum, and vinblastine and molecular targeted therapy based on the genetic test results of patients have certain efficacy. Here, we report a 79-year-old male case diagnosed with human epidermal growth factor receptor 2 (HER-2) overexpression, which was effectively controlled by chemotherapy and anti\u2013HER-2 treatment such as pyrotinib.<\/jats:p>","DOI":"10.3389\/fonc.2024.1382376","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T04:30:35Z","timestamp":1720499435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Pyrotinib in the treatment of advanced scrotal EMPD combined with sweat gland carcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Liquan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.critrevonc.2016.03.008","article-title":"Paget disease of the vulva","volume":"101","author":"van der Linden","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"154283","DOI":"10.1016\/j.prp.2022.154283","article-title":"Extramammary paget disease of the penoscrotal region","volume":"241","author":"Patwardhan","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65516-4","article-title":"Extramammary Paget\u2019s disease of the penis and scrotum: excision, reconstruction and evaluation of occult Malignancy","volume":"166","author":"Park","year":"2001","journal-title":"J Urol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002064","article-title":"Extramammary paget disease: A review of the literature-part I: history, epidemiology, pathogenesis, presentation, histopathology, and diagnostic work-up","volume":"46","author":"Morris","year":"2020","journal-title":"Dermatol Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01114","article-title":"Clinical characteristics, treatment, and prognostic factors of patients with primary extramammary paget\u2019s disease (EMPD): A retrospective analysis of 44 patients from a single center and an analysis of data from the surveillance, epidemiology, and end results (SEER) database","volume":"10","author":"Weng","year":"2020","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.hoc.2018.09.003","article-title":"Extramammary paget\u2019s disease","volume":"33","author":"Asel","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/01455613211016717","article-title":"Sweat gland carcinoma of the head and neck: case\u00a0report and literature review","author":"Zhang","year":"2021","journal-title":"Ear Nose Throat J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2005.12.011","article-title":"Sweat-gland tumours: a clinical review of cases in one centre over 20 years","volume":"18","author":"Hall","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.919444","article-title":"Syringoid eccrine carcinoma in the abdominal wall: A rare case report and literature review","volume":"20","author":"Pereira","year":"2019","journal-title":"Am J Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00330-0","article-title":"Eccrine sweat gland carcinoma of the scrotum with associated extramammary Paget\u2019s disease","volume":"50","author":"Saidi","year":"1997","journal-title":"Urology."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2002.124788","article-title":"Vulvar Paget disease of urothelial origin: a report of three cases and a proposed classification of vulvar Paget disease","volume":"33","author":"Wilkinson","year":"2002","journal-title":"Hum Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.01.032","article-title":"Treatment outcomes in a large cohort of patients with invasive Extramammary Paget\u2019s disease","volume":"125","author":"Karam","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B13","article-title":"[Clear cell adenomyoepithelioma of the ceruminous gland]","volume":"100","author":"Di Blasi","year":"2008","journal-title":"Pathologica."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP2N1AFXEFOVYE","article-title":"Immunohistochemical distinction of primary sweat\u00a0gland carcinoma and metastatic breast carcinoma: can it always be accomplished reliably","volume":"143","author":"Mentrikoski","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2008.01087.x","article-title":"Differential expression of mucin core proteins and keratins in apocrine carcinoma, extramammary Paget\u2019s disease and apocrine nevus","volume":"36","author":"Miyamoto","year":"2009","journal-title":"J Cutan Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12893-019-0595-4","article-title":"A case of eccrine porocarcinoma characterized by a progressive increase in the level of Ki-67 index: case report and review of literature","volume":"19","author":"Shen","year":"2019","journal-title":"BMC Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-014-0686-2","article-title":"Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget\u2019s disease","volume":"20","author":"Tokuda","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13693","article-title":"Achieved good response of S-1 and docetaxel combination chemotherapy in two patients with metastatic extramammary Paget\u2019s disease","volume":"44","author":"Egashira","year":"2017","journal-title":"J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2013.168.issue-6","article-title":"Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease","volume":"168","author":"Tanaka","year":"2013","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2011.v5.4.151","article-title":"The expression of HER-2 in extramammary Paget\u2019s disease","volume":"5","author":"Masuguchi","year":"2011","journal-title":"Biosci Trends."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/cancers15061803","article-title":"Vulvar paget\u2019s disease: A systematic review of the MITO rare cancer group","volume":"15","author":"Caruso","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.925551","article-title":"Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin","volume":"12","author":"Zattarin","year":"2022","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00204","article-title":"Case of metastatic extramammary paget disease of the vulva treated successfully with trastuzumab emtansine","volume":"2","author":"Hsieh","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.3390\/cancers14163996","article-title":"Overcoming resistance to HER2-directed therapies in breast cancer","volume":"14","author":"Schlam","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S244814","article-title":"Response to pyrotinib in a chinese patient with bone-metastatic scrotal paget\u2019s disease harboring triple uncommon HER2 mutation: A case report","volume":"13","author":"Guo","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.6179","article-title":"Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-erbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"35","author":"Ma","year":"2017","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4173","article-title":"Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00108","article-title":"Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: A randomized, phase II study","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1382376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T04:30:39Z","timestamp":1720499439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1382376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":30,"alternative-id":["10.3389\/fonc.2024.1382376"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1382376","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"article-number":"1382376"}}